• Disease Overview
  • Synonyms
  • Signs & Symptoms
  • Causes
  • Affected Populations
  • Disorders with Similar Symptoms
  • Diagnosis
  • Standard Therapies
  • Clinical Trials and Studies
  • References
  • Programs & Resources
  • Complete Report
Select language / seleccionar idioma:

C Syndrome


Last updated: November 19, 2020
Years published: 1992, 2005, 2020


NORD gratefully acknowledges Mounya Duggal, MDCM Candidate, McGill University School of Medicine, and Roser Urreizti, PhD, Biochemistry Laboratory and Neurometabolical Diseases Unit, Institut de Recerca Hospital Sant Joan de Deu, CIBERER, Barcelona, Spain for assistance in the preparation of this report.

Disease Overview


C syndrome, also known as Opitz trigonocephaly syndrome (OTCS), is a complex condition defined by a broad group of clinical features and abnormalities. Children may be given this preliminary diagnosis and later diagnosed with a specific genetic condition. Affected children are born with a malformation in which the head is a triangular shape due to premature union of the skull bones (trigonocephaly), a narrow pointed forehead, a flat broad nasal bridge with a short nose, vertical folds over the inner corners of the eyes, an abnormal palate that is deeply furrowed, abnormalities of the ear, crossed eyes (strabismus), joints that are bent or in a fixed position, and loose skin. Developmental and learning disabilities are common. These signs and symptoms can vary significantly from one patient to another.

OTCS is a heterogeneous disorder, which means that it does not have a single cause. Changes (mutations) in multiple and distinct genes, combinations of genes and chromosomal abnormalities may be the underlying cause this condition.


In 1969, John Marius Opitz, a German-American medical geneticist, was treating two siblings, one brother and one sister. He noticed similar features: trigonocephaly, facial dysmorphia and severe mental delay. The syndrome was first named “C syndrome of multiple congenital abnormalities”, where the “C” stood for this family’s surname. Then, it was renamed C syndrome, Opitz C syndrome or Opitz trigonocephaly syndrome.

  • Next section >
  • < Previous section
  • Next section >


  • Opitz trigonocephaly syndrome
  • trigonocephaly C syndrome
  • trigonocephaly syndrome
  • OTCS
  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Signs & Symptoms

One of the major features of OTCS is a condition in which the skull is a triangular shape. This occurs due to premature closure of the bones (trigonocephaly or prominent metopic suture due to its premature fusion). Patients with this disorder also have a distinct face in which the nasal bridge is broad with a short nose, there are vertical folds over the inner corners of the eyes (epicanthus) and paralysis of facial muscles (facial palsy). These children may have abnormalities of the outer ear, crossed eyes (strabismus), thin upper lip, smooth vertical groove between the base of the nose and the border of the upper lip (philtrum),an undersized jaw (micrognathia), a short neck and loose skin. Additional characteristics can include abnormalities of the breastbone (sternum), webbed fingers and/or toes (syndactyly), short limbs, heart, pancreas, kidney and lung abnormalities and failure of one or both testicles to move down into the scrotum (cryptorchidism).

Feeding difficulties may occur because of a deeply furrowed palate in the mouth and malposition of teeth. Additional characteristics can include loss of muscle tone and joints in the hands bent in a fixed position or dislocated.

Affected children may have central nervous system malformations and seizures. Developmental delay (motor, mental or global) and speech delay are common and children with C syndrome have intellectual disability that can vary from mild to severe.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


There is no common genetic cause for OTCS. Recent research has found that changes (mutations) in specific genes could be associated with this condition: MAGEL2, FOXP1, IFT140 and ASXL3.

Until recently, OTCS was thought to follow an autosomal recessive pattern of inheritance. However, it is now believed that the disorder occurs as a result of de novo dominant heritance or gonadal mosaicism. Mosaicism refers to a condition in which a person has cells that differ from each other in genetic makeup.

Dominant genetic disorders occur when only a single copy of an altered gene is necessary to cause a particular disease. The altered gene can be inherited from an affected parent or can be the result of a new change (mutation) in the affected individual. The risk of passing the altered gene from an affected parent to an offspring is 50% for each pregnancy. The risk is the same for males and females.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Affected populations

Only about 60 patients with OTCS have been reported in the world’s medical literature. OTCS is a very rare disorder that seems to affect males and females in equal numbers. The prevalence is between 1/800,000 and 1/1,000,000.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


OTCS is a clinical diagnosis based on the features mentioned earlier. Since multiple genes (and chromosomal abnormalities) may be associated with this condition, whole exome sequencing (WES) can be used to identify the underlying molecular cause in some patients clinically diagnosed with this condition.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Standard Therapies

There is no specific treatment for OTCS but treatment for some symptoms is possible. When trigonocephaly is severe, surgery may be performed to relieve the pressure on the brain and improve facial appearance. Other surgical procedures may be indicated for heart and other malformations. Supportive therapies such as speech therapy and interdisciplinary rehabilitation may be helpful in some patients. Genetic counseling is recommended for patients and their families.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Clinical Trials and Studies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: prpl@cc.nih.gov

Some current clinical trials also are posted on the following page on the NORD website: https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/

For information about clinical trials sponsored by private sources, contact: http://www.centerwatch.com/

For information about clinical trials conducted in Europe, contact: https://www.clinicaltrialsregister.eu/

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


Bohring A. C Syndrome. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:162-63.

Gorlin RJ, Cohen MM Jr, Levin LS., eds. Syndromes of the Head and Neck. 3rd ed. Oxford University Press, London, UK; 1990:889-90

Urreizti R, Grinberg D, Balcells S. C syndrome – what do we know and what could the future hold? Expert Opinion on Orphan Drugs. 2019;7(3):91-94. https://www.tandfonline.com/doi/full/10.1080/21678707.2019.1589448?fbclid=IwAR2clHG8fnE8ZdOxRPGBMiqCnjGnc1kUMclvImDv3GfZxvJHM4HP_Ds5ntU

Urreizti R, Damanti S, Esteve C, et al. A De Novo FOXP1 truncating mutation in a patient originally diagnosed as c syndrome. Sci Rep. 2018;8. www.ncbi.nlm.nih.gov/pmc/articles/PMC5766530/.

Peña‐Padilla C, Marshall CR, Walker S, et al. Compound heterozygous mutations in the IFT140 gene cause opitz trigonocephaly c syndrome in a patient with typical features of a ciliopathy. Clinical Genetics. 2017;91(4):640-646. https://pubmed.ncbi.nlm.nih.gov/27874174/.

Urreizti R, Cueto-Gonzalez AM, Franco-Valls H, et al. A de novo nonsense mutation in magel2 in a patient initially diagnosed as opitz-c: similarities between Schaaf-Yang and Opitz-c syndromes. Sci Rep. 2017;7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345063/.

Alvina Fierro JA, Hernandez Avina DA. Opitz c syndrome: trigonocephaly, mental retardation and craniofacial dysmorphism.
Elsevier. 2016;17:125-129. https://www.sciencedirect.com/science/article/pii/S1110863015000531.

Urreizti R, Roca‐Ayats N, Trepat J, et al. Screening of CD96 and ASXL1 in 11 patients with Opitz c or Bohring–Opitz syndromes. American Journal of Medical Genetics Part A. 2016;170(1):24-31. https://pubmed.ncbi.nlm.nih.gov/26768331/.

Yatsenko SA, Cheung SW, Scott DA, et al. Deletion of 9q34.3 syndrome: genotype-phenotype correlations and an extended deletion in a patient with feature of Opitz C trigonocephaly. J Med Genet. 2005;42:328-35.

Czako M, Riegel M, Morava E, et al. Opitz “C” trigonocephaly-like syndrome in a patient with terminal deletion of 2p and partial duplication of 17q. Am J Med Genet A. 2004;131:310-12.

Phadke SR, Patil SJ. Partial trisomy 13 with features similar to C syndrome. Indian Pediatr. 2004;41:614-17.

Azimi C, Kennedy SJ, Chitayat D, et al. Clinical and genetic aspects of trigonocephaly: a study of 25 cases. Am J Med Genet A. 2003;117:127-35.

Miller C, Losken HW, Towbin R, et al. Ultrasound diagnosis of craniosynostosis. Cleft Palate Craniofac J. 2002;39:73-80.

Bohring A, Silengo M, Lerone M, et al. Severe end of Opitz trigonocephaly © syndrome or new syndrome. Am J Med Genet. 1999;85:438-46.

  • < Previous section
  • Next section >

Programs & Resources

RareCare® Assistance Programs

NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.

Additional Assistance Programs

MedicAlert Assistance Program

NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.

Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/

Rare Disease Educational Support Program

Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.

Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/

Rare Caregiver Respite Program

This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.

Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/

Patient Organizations

National Organization for Rare Disorders